Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

ClinicalTrials.gov ID: NCT05911841

Public ClinicalTrials.gov record NCT05911841. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 12:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, 52 Week Study to Evaluate the Efficacy and Safety of LY3454738 in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main purpose of this study is to describe the efficacy and safety of LY3454738 in adult participants with moderate-to-severe atopic dermatitis (AD).

Study identification

NCT ID
NCT05911841
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Eli Lilly and Company
Industry
Enrollment
234 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 20, 2023
Primary completion
Oct 9, 2024
Completion
Mar 13, 2025
Last update posted
Dec 1, 2025

2023 – 2025

United States locations

U.S. sites
13
U.S. states
10
U.S. cities
13
Facility City State ZIP Site status
Johnson Dermatology Fort Smith Arkansas 72916
Arkansas Research Trials North Little Rock Arkansas 72217
Dermatology Research Associates Los Angeles California 90045
Encore Medical Research Hollywood Florida 33024
Conquest Research Winter Park Florida 32789
Allergy and Asthma Specialist Owensboro Kentucky 42301
Revival Research Institute, LLC Troy Michigan 48084
ActivMed Practices & Research, Inc. Portsmouth New Hampshire 03801
Metropolitan Dermatology - Clark Kenilworth New Jersey 07033
Oregon Dermatology and Research Center Portland Oregon 97210
DermDox Centers for Dermatology Camp Hill Pennsylvania 17011
Progressive Clinical Research San Antonio Texas 78213
Center for Clinical Studies Webster Texas 77598

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05911841, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 1, 2025 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05911841 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →